Drugs / EPTACOG ALFA PEGOL (ACTIVATED)
EPTACOG ALFA PEGOL (ACTIVATED)
also known as
activated recombinant human factor VII, long acting · Eptacog alfa pegol (activado) · Eptacog alfa pegol (active)
Protein / enzyme biologic targets F7
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00951873 | Jul 2009 → Apr 2010 | hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00922792 | Jun → Sep 2009 | congenital hematological disorder, hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPTACOG ALFA PEGOL (ACTIVATED) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108292 ↗ |
| Known as | activated recombinant human factor VII, long acting | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00951873 ↗ |
| Known as | Eptacog alfa pegol (activado) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108292 ↗ |
| Known as | Eptacog alfa pegol (active) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108292 ↗ |
| Modality | Protein / enzyme biologic | “activated recombinant human factor VII” NCT00922792 ↗ |
| Route | Intravenous | “injected i.v. (intravenous)” NCT00922792 ↗ |
| Target | F7 | “Coagulation factor VII exogenous protein” CHEMBL2108292 ↗ |